SERVICES
ONCOLYTIC VIRUS SYNTHESIS AND PRODUCTION
Seagull Biosolutions has produced SBPL-0600 – a recombinant Measles virus that expresses upto 4 different proteins inside tumor cells. This virus has been shown in nude mice to (1) inhibit the growth of Lung Cancer & Prostate Cancer and (2) inhibit the inflammatory changes which occur in these tumor xenografts. Moreover, using an ex vivo Tumor Necrosis Assay, SBPL has also shown that treatment with SBPL-0600 can stimulate human PBMCs to kill cancer cells efficiently.
SBPL now offers a service to produce recombinant MV derivatives for use as Oncolytic Immunoviro therapies.
ACTIVE VIROSOME SYNTHESIS
Active Virosomes – are non-replicating Measles derivatives which display different viral or non-viral membrane proteins and are useful as antigens in discovery of novel Membrane Protein targeted biopharmaceuticals and as Vaccines. SBPL has already produced such AV antigens for Dengue (all 4 serotypes), Chikungunya, Zika & Ebola virus vaccine development. Additionally AVs expressing human GPCRs have also been produced. SBPL now offers a service to produce AVs expressing Membrane Proteins (AV-MP) to interested clients
GENE CLONING AND EXPRESSION
SBPL has developed expertise in cloning & expression of genes in eukaryotic cells. Specifically SBPL is currently offering services for expression of genes using a novel MV-RdRP mediated gene expression system.
PSEUDOVIRUS NEUTRALISATION ASSAY
Active Virosomes – are by nature pseudoviruses derived from the vaccine strain of Measles Virus. As such they are inherently safe and can be used to express a wide range of membrane proteins from different viral pathogens. SBPL has already produced AVs expressing membrane proteins from Dengue, Chikungunya, Zika & Ebola viruses and has shown that these AV agents can infect animal cells and express the genes encoded by their replicon RNA genome in these animal cells. These AV agents have been shown to be useful for developing non-hazardous Pseudovirus neutralizing tests for detection of neutralizing antibodies reactive to different viral pathogens. Currently SBPL is developing a similar Pseudovirus Neutralization assay for SARS-CoV-2 virus.